On the relationship between the causal-inference and meta-analytic paradigms for the validation of surrogate endpoints-Reference-Cited by-同舟云学术

On the relationship between the causal-inference and meta-analytic paradigms for the validation of surrogate endpoints

Published:2014-10-01 Issue:1 Volume:71 Page:15-24
ISSN:0006-341X
Container-title:Biometrics
language:en
Short-container-title:Biom

Author:

Alonso Ariel¹,Van der Elst Wim²,Molenberghs Geert²³,Buyse Marc²⁴,Burzykowski Tomasz²⁴

Affiliation:

1. Department of Methodology and Statistics; Maastricht University; Maastricht the Netherlands

2. I-BioStat; Universiteit Hasselt; B-3590 Diepenbeek Belgium

3. I-BioStat; Katholieke Universiteit Leuven; B-3000 Leuven Belgium

4. International Drug Development Institute (IDDI); Louvain-la-Neuve; Belgium

Publisher

Wiley

Subject

Applied Mathematics,General Agricultural and Biological Sciences,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine,Statistics and Probability

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/biom.12245/fullpdf

Reference19 articles.

1. Burzykowski , T. Molenberghs , G. Buyse , M. 2005

2. The validation of surrogate endpoints in randomized experiments;Buyse;Biometrics,1998

3. The validation of surrogate endpoints in meta-analyses of randomized experiments;Buyse;Biostatistics,2000

4. Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal;Conlon;Biostatistics,2013

5. Choice of units of analysis and modeling strategies in multilevel hierarchical models;Cortiñas Abrahantes;Computational Statistics and Data Analysis,2004

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer;European Urology;2024-08

2. Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration;BMJ;2024-07-09

3. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration;BMJ;2024-07-09

4. Proportion of treatment effect explained: An overview of interpretations;Statistical Methods in Medical Research;2024-07

5. Quantifying proportion of treatment effect by surrogate endpoint under heterogeneity;Statistical Methods in Medical Research;2024-05-08